Please give feedback on our site!

  • KDIGO Conference Held on ADPKD

    The first-ever Controversies Conference organised by KDIGO on Autosomal Dominant Polycystic Kidney Disease (ADPKD) was held in Edinburgh from 16 to 19 January 2014.

    Consensus recommendations were made by more than 60 globally-recognized experts.

    This was KDIGO’s 15th Controversies Conference which, for the first time, included patient representatives among its participants from Europe, the US and Japan. The PKD Charity was represented by Tess Harris, who co-chaired the patient work group which focused on 'Practical Integrated Patient Support'.

    Read more...

    Kidney Health Report October 2013

    The report 'Kidney Health: Delivering Excellence' was published on 17 October 2013 and identifies the challenges ahead for the UK renal community.

    Read more...

    Tolvaptan News

    Click here for the latest news on Tolvaptan

  • Otsuka Submits Application to EMA

    In late December 2013, Otsuka Pharmaceutical Co Ltd submitted an application to the European Medicines Agency (EMA) for marketing authorisation of tolvaptan for the treatment of ADPKD in Europe.

    The EMA considers marketing application authorisations (MAA) at the monthly meeting of its Committee for Medicinal Products for Human Use (CHMP). It is understood that the process could take 6 months. We will let everyone know the outcome immediately.

     

    FDA Advisory Committee Votes Against Tolvaptan

    On 5 August, 2013, the US Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee met to review the Tolvaptan submission for product licensing.

    Read more...

    PKD Research Papers

    Here we list published papers on the most important studies into PKD in the past few years. These are either direct links to Papers in the public domain or to an Abstract.

    Read more...

Find out more about PKD

ADPKD - AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE - is the world’s most common inherited kidney disease, in which fluid-filled cysts develop, multiply and grow in both kidneys. Other organs, such as the liver and brain, may be affected. Between 1 in 400 and 1 in 1000 people worldwide - about 12.5 million - have ADPKD. Over half of those affected will have kidney failure by the time they are 60 years old. Many will experience regular pain, disabiity and anxiety throughout life. If someone has ADPKD, there is a 1 in 2 (50 percent) likelihood that the disease will pass to each child born.

Read more about ADPKD.

ARPKD - AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE - is a rare disease that affects the kidneys and liver. It occurs in about one in every 20,000 live births in the UK. ARPKD is a severe disease. Sadly, about one baby in three with ARPKD dies from breathing problems during the first four weeks after birth and some will die during pregnancy. However, 8 to 9 in ten babies (80-90 per cent) who survive the first four weeks of life are still alive at five years old. Encouragingly, a good number of children  now survive into adulthood and are able to live full and productive lives.

Read more about ARPKD.

 

Latest Tweets

#nhsparticipation Prioritisation tools will inform commissioning round 2015-16

PKD Charity UK PKD Charity UK

PKD Charity is a Member of

Visit Ciliopathy Alliance websiteVisit PKD International websiteVisit EURORDIS websiteVisit the Genetic Alliance UK website
Visit The Information Standard websiteTransplant 2013 WebsiteNational Voices WebsiteRare Disease UK Website
Remeber a Charity WebsiteSpecialised Healthcare Alliance WebsiteFEDERG Website